Nivagen Pharms Inc Company Profile
✉ Email this page to a colleague
What is the competitive landscape for NIVAGEN PHARMS INC, and what generic and branded alternatives to NIVAGEN PHARMS INC drugs are available?
NIVAGEN PHARMS INC has five approved drugs.
Summary for Nivagen Pharms Inc
| US Patents: | 0 |
| Tradenames: | 5 |
| Ingredients: | 5 |
| NDAs: | 5 |
Drugs and US Patents for Nivagen Pharms Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nivagen Pharms Inc | CALCIUM GLUCONATE | calcium gluconate | SOLUTION;INTRAVENOUS | 213071-003 | Apr 30, 2024 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
| Nivagen Pharms Inc | CALCIUM GLUCONATE | calcium gluconate | SOLUTION;INTRAVENOUS | 213071-002 | Oct 19, 2023 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
| Nivagen Pharms Inc | ZINC SULFATE | zinc sulfate | SOLUTION;INTRAVENOUS | 214597-002 | Jul 5, 2024 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
| Nivagen Pharms Inc | ZINC SULFATE | zinc sulfate | SOLUTION;INTRAVENOUS | 214597-003 | Jul 5, 2024 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
| Nivagen Pharms Inc | TEMOZOLOMIDE | temozolomide | CAPSULE;ORAL | 213328-001 | Nov 23, 2021 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | |||||
| Nivagen Pharms Inc | CALCIUM GLUCONATE | calcium gluconate | SOLUTION;INTRAVENOUS | 213071-001 | Oct 14, 2022 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
